Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study

Atherosclerosis

Volumn 206, Issue 1, 2009, Pages 265-269

  Sandhofer, A ^a   Tatarczyk, T ^a   Kirchmair, R ^a   Iglseder, B ^b   Paulweber, B ^b   Patsch, J R ^a   Schratzberger, P ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Atherogenesis atherosclerosis; Intima media thickness; sFlt 1; VEGF

Indexed keywords

C REACTIVE PROTEIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; AGE; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; BODY MASS; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; HUMAN; INSULIN RESISTANCE; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; THROMBOCYTE COUNT;

CAROTID ARTERIES; CAROTID ARTERY DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 68949197504     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.01.031     Document Type: Article

References (32)

1. Asahara T., Chen D., Tsurumi Y., et al. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation 94 (1996) 3291-3302
2. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26 (2001) 25-35
3. Barleon B., Reusch P., Totzke F., et al. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 4 (2001) 143-154
4. Roeckl W., Hecht D., Sztajer H., et al. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp Cell Res 241 (1998) 161-170
5. Hornig C., Barleon B., Ahmad S., et al. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 80 (2000) 443-454
6. Hoshida T., Sunamura M., Duda D.G., et al. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas 25 (2002) 111-121
7. Asahara T., Bauters C., Pastore C., et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 91 (1995) 2793-2801
8. Tsurumi Y., Kearney M., Chen D., et al. Treatment of acute limb ischemia by intramuscular injection of vascular endothelial growth factor gene. Circulation 96 (1997) II-382-8
9. Schratzberger P., Schratzberger G., Silver M., et al. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat Med 6 (2000) 405-413
10. Fortuin F.D., Vale P., Losordo D.W., et al. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol 92 (2003) 436-439
11. Schratzberger P., Walter D.H., Rittig K., et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 107 (2001) 1083-1092
12. Celletti F.L., Waugh J.M., Amabile P.G., et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 7 (2001) 425-429
13. Luttun A., Tjwa M., and Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann NY Acad Sci 979 (2002) 80-93
14. Zhao Q., Egashira K., Hiasa K., et al. Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury. Arterioscler Thromb Vasc Biol 24 (2004) 2284-2289
15. Heeschen C., Dimmeler S., Hamm C.W., et al. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 107 (2003) 524-530
16. Belgore F.M., Blann A.D., Li-Saw-Hee F.L., Beevers D.G., and Lip G.Y. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 87 (2001) 805-7, A9
17. Belgore F.M., Lip G.Y., and Blann A.D. Successful therapy reduces levels of vascular endothelial growth factor (VEGF) in patients with hypertension and patients with hypercholesterolemia. Atherosclerosis 151 (2000) 599
18. Blann A.D., Belgore F.M., Constans J., Conri C., and Lip G.Y. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 87 (2001) 1160-1163
19. Kimura K., Hashiguchi T., Deguchi T., et al. Serum VEGF-as a prognostic factor of atherosclerosis. Atherosclerosis 194 (2007) 182-188
20. Esterbauer H., Schneitler C., Oberkofler H., et al. A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet 28 (2001) 178-183
21. Sandhofer A., Iglseder B., Paulweber B., Ebenbichler C.F., and Patsch J.R. Comparison of different definitions of the metabolic syndrome. Eur J Clin Invest 37 (2007) 109-116
22. Graci S., Baratta R., Degano C., et al. The intravenous insulin tolerance test is an accurate method for screening a general population for insulin resistance and related abnormalities. J Endocrinol Invest 22 (1999) 472-475
23. Rationale and design for the Asymptomatic Carotid Artery Plaque Study (ACAPS). The ACAPS Group. Control Clin Trials 13 (1992) 293-314
24. Schmidt H., Schmidt R., Niederkorn K., et al. Beta-fibrinogen gene polymorphism (C148 → T) is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Arterioscler Thromb Vasc Biol 18 (1998) 487-492
25. Holzl B., Iglseder B., Stadlmayr A., et al. Intima media thickness of carotid arteries is reduced in heterozygous carriers of the Gly972Arg variant in the insulin receptor substrate-1 gene. Eur J Clin Invest 33 (2003) 110-116
26. Faul F., Erdfelder E., Lang A.G., and Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Meth 39 (2007) 175-191
27. Felmeden D.C., Spencer C.G., Belgore F.M., et al. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 16 (2003) 11-20
28. Felmeden D.C., Spencer C.G., Chung N.A., et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol 92 (2003) 400-405
29. Felmeden D.C., Spencer C.G., Blann A.D., Beevers D.G., and Lip G.Y. Physical activity in relation to indices of endothelial function and angiogenesis factors in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Intern Med 253 (2003) 81-91
30. Lim H.S., Blann A.D., Chong A.Y., Freestone B., and Lip G.Y. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention. Diab Care 27 (2004) 2918-2924
31. Banks R.E., Forbes M.A., Kinsey S.E., et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 77 (1998) 956-964
32. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340 (1999) 14-22